menu
    • menu
    [{"orgOrder":0,"company":"Oscotec","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cevidoplenib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ Not Applicable"},{"orgOrder":0,"company":"Oscotec","sponsor":"Beactica","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Termination","leadProduct":"BEA-17","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oscotec","amount2":0.17999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Oscotec \/ Oscotec","highestDevelopmentStatusID":"4","companyTruncated":"Oscotec \/ Oscotec"},{"orgOrder":0,"company":"Oscotec","sponsor":"ADEL Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ADEL-Y01","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Oscotec \/ ADEL Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Oscotec \/ ADEL Inc."},{"orgOrder":0,"company":"Oscotec","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cevidoplenib","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ Not Applicable"},{"orgOrder":0,"company":"Oscotec","sponsor":"ADEL Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"ADEL-Y01","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oscotec \/ ADEL Inc","highestDevelopmentStatusID":"6","companyTruncated":"Oscotec \/ ADEL Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Oscotec

    Menu

    Oscotec

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oscotec

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Oscotec

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cevidoplenib

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Orphan Drug Designation to Cevidoplenib for ITP

                            Details : SKI-O-703 (cevidoplenib) is a SYK inhibitor, small molecule drug candidate, which is being evaluated for the treatment of patients with immune thrombocytopenia.

                            Brand Name : SKI-O-703

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 21, 2024

                            Lead Product(s) : Cevidoplenib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oscotec

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Oscotec

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADEL-Y01

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : ADEL Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oscotec/ADEL Doses First Patient in Phase 1 for ADEL-Y01 in Alzheimer’s Disease

                            Details : ADEL-Y01 is a recombinant IgG1 class type monoclonal humanized antibody that binds to tau protein acetylated at lysine-280, which is investigated for the treatment of alzheimer's disease.

                            Brand Name : ADEL-Y01

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 23, 2024

                            Lead Product(s) : ADEL-Y01

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : ADEL Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oscotec

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Oscotec

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADEL-Y01

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : ADEL Inc.

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease

                            Details : ADEL-Y01 is a recombinant IgG1 class type monoclonal humanized antibody that binds to tau protein acetylated at lysine-280, which is investigated for the treatment of alzheimer's disease.

                            Brand Name : ADEL-Y01

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 14, 2023

                            Lead Product(s) : ADEL-Y01

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : ADEL Inc.

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Oscotec

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Oscotec

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BEA-17

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Beactica

                            Deal Size : $178.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Beactica Therapeutics and Oscotec Mutually Agree to Conclude Oncology Collaboration

                            Details : Under the agreement, Beactica Therapeutics will retain full exclusive global rights for further development and commercialization of the LSD1 programme, including BEA-17, a first-in-class small molecule targeted degrader of the epigenetic enzyme LSD1 and...

                            Brand Name : BEA-17

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 04, 2023

                            Lead Product(s) : BEA-17

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Beactica

                            Deal Size : $178.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Oscotec

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Oscotec

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cevidoplenib

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oscotec Announces Topline Results for Phase 2 Trial of Cevidoplenib

                            Details : SKI-O-592 (cevidoplenib) binds to and inhibits SYK activity, blocking Fc receptor and BCR-mediated signaling in inflammatory cells. This leads to the inhibition of the related inflammatory responses and tissue damage. It is being developed for immune thr...

                            Brand Name : SKI-O-592

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 24, 2023

                            Lead Product(s) : Cevidoplenib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth